Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: docetaxel+lapatinib|DRUG: docetaxel + trastuzumab|DRUG: docetaxel + trastuzumab + lapatinib
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Collaborators: GlaxoSmithKline